Early access
Sign in
Taking peopleNo phase

Disease Activity Monitoring in Patients With Giant Cell Arteritis Study

Key facts

Who runs it
University of Aarhus
Where
Denmark7 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
175 people, planned
Started
6 May 2026
Expected to end
Feb 2029
Type of study
Observational
Record updated
31 August 2026

Who can take part

Age
50 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Clinical GCA diagnosis established/confirmed by a rheumatologist and positive GCA imaging or biopsy at diagnosis < 3 years
  • Clinical remission at the time of inclusion, defined as; Having adhered for ≥ 8 weeks prior to inclusion to either (a) the planned tapering of glucocorticoid therapy, or (b) the planned glucocorticoid-sparing DMARD treatment (with or without glucocorticoids); Absence of, or no worsening of, symptoms attributed to GCA in ≥ 8 weeks; Normal CRP level (< 10 mg/L) within 7 days before inclusion
  • Current prednisolone dosage of ≥ 5 mg if glucocorticoid monotherapy
  • A continuous tapering of monotherapy or combination therapy is planned
  • Age > 50 years
  • Study participants must be able to speak and understand spoken and written Danish

Who cannot take part

  • Intra-articular, intravenous or intramuscular glucocorticoid ≤ 7 weeks prior to inclusion
  • Presence of cognitive impairment, including clinically significant dementia, that may interfere with the ability to provide informed consent or comply with study procedures
  • Study participants who are unable to complete online questionnaires cannot participate in the GCA-PRO component of the study

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Giant Cell Arteritis (GCA) is a vasculitis of medium- and large-sized arteries in older adults that may lead to serious vascular complications, including permanent vision loss and aortic aneurysm formation. Glucocorticoids are effective, but relapse during tapering is common and poses a major clinical challenge, potentially contributing to prolonged glucocorticoid exposure. Symptoms are often nonspecific and conventional inflammatory markers lack sufficient reliability, particularly in patients treated with drugs targeting the interleukin-6 pathway. Thus, this project aims to evaluate different tools assisting disease activity monitoring and/or predict future relapses and higher treatment requirements. Up to 175 patients with GCA in remission will be enrolled to ensure that 144 participants complete 1 year of follow-up. Participants undergo vascular ultrasonography, including double-blinded assessment at suspected relapse, complete patient-reported outcome measures, and provide biobank blood samples.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Disease Activity Monitoring in Patients With Giant Cell Arteritis
Record updated
31 August 2026